Murray CJ, Aravkin AY, Zheng P, Abbafati C, Abbas KM, Abbasi-Kangevari M, Abd-Allah F, Abdelalim A, Abdollahi M, Abdollahpour I. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of Disease Study 2019. Lancet. 2020;396(10258):1223–49.

Article  Google Scholar 

Ramage S, Farmer A, Apps Eccles K, McCargar L. Healthy strategies for successful weight loss and weight maintenance: a systematic review. Appl Physiol Nutr Metab. 2014;39(1):1–20.

Article  CAS  PubMed  Google Scholar 

Hruby A, Hu FB. The epidemiology of obesity: a big picture. PharmacoEconomics. 2015;33:673–89.

Article  PubMed  PubMed Central  Google Scholar 

Chu P-Y, Yu Y-C, Pan Y-C, Dai Y-H, Yang J-C, Huang K-C, Wu Y-C. The efficacy of Lactobacillus delbrueckii ssp. bulgaricus supplementation in managing body weight and blood lipids of people with overweight: a Randomized Pilot Trial. Metabolites. 2024;14(2):129.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McLachlan S, Collaboration NRF. Trends in adult body mass index in 200 countries since 1975: pooled analysis of 1,698 population-based measurement studies with 19.2 million participants. Lancet 2016, 387(10026).

Li P, Huang Y, Wong A. Behavioural strategies to reduce obesity among lower socioeconomic adults living in high-income countries: a GRADE-assessed systematic review and meta-analysis of randomised controlled trials. Br J Nutr 2023:1–24.

Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020;75(2):235.

Article  PubMed  PubMed Central  Google Scholar 

Machado AM, Guimarães NS, Bocardi VB, da Silva TPR, do, Carmo AS, de Menezes MC, Duarte CK. Understanding weight regain after a nutritional weight loss intervention: systematic review and meta-analysis. Clinical nutrition ESPEN 2022, 49:138–153.

Reis MG, Moreira LFGG, de Andrade Carvalho LSV, de Castro CT, Vieira RAL, Guimarães NS. Weight regain after bariatric surgery: a systematic review and meta-analysis of observational studies. Obes Med 2023:100528.

Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine. 2023;58:101882.

Article  PubMed  PubMed Central  Google Scholar 

Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art. Mol Metabolism. 2021;46:101102.

Article  CAS  Google Scholar 

Klein T, Augustin R, Hennige AM. Perspectives in weight control in diabetes–survodutide. Diabetes Res Clin Pract. 2024;207:110779.

Article  CAS  PubMed  Google Scholar 

Zimmermann T, Thomas L, Baader-Pagler T, Haebel P, Simon E, Reindl W, Bajrami B, Rist W, Uphues I, Drucker DJ. BI 456906: discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metabolism. 2022;66:101633.

Article  CAS  Google Scholar 

le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162–73.

Article  PubMed  Google Scholar 

Yazawa R, Ishida M, Balavarca Y, Hennige AM. A randomized phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide‐1 receptor agonist, in healthy Japanese men with overweight/obesity. Diabetes Obes Metabolism. 2023;25(7):1973–84.

Article  CAS  Google Scholar 

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Reviews. 2015;4(1):1.

Article  Google Scholar 

Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Assessing risk of bias in a randomized trial. Cochrane Handb Syst Reviews Interventions 2019:205–28.

Schwingshackl L, Knüppel S, Schwedhelm C, Hoffmann G, Missbach B, Stelmach-Mardas M, Dietrich S, Eichelmann F, Kontopantelis E, Iqbal K, et al. Perspective: NutriGrade: a Scoring System to assess and judge the Meta-evidence of Randomized controlled trials and Cohort studies in Nutrition Research. Adv Nutr. 2016;7(6):994–1004.

Article  PubMed  PubMed Central  Google Scholar 

Higgins J. Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. www cochrane-handbook org 2011.

Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13.

Article  PubMed  PubMed Central  Google Scholar 

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.

Article  PubMed  PubMed Central  Google Scholar 

Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, Anstee QM, Hussain SA, Newsome PN, Ratziu V. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. The New England journal of medicine.

Jungnik A, Arrubla Martinez J, Plum-Mörschel L, Kapitza C, Lamers D, Thamer C, Schölch C, Desch M, Hennige AM. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906. Diabetes Obes Metabolism. 2023;25(4):1011–23.

Article  CAS  Google Scholar 

Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. And bodyweight reduction of survodutide, a dual glucagon/GLP–1 receptor agonist, compared with placebo and open–label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2023;67:470–82.

Article  PubMed  PubMed Central  Google Scholar 

Borenstein M, Cooper H, Hedges L, Valentine J. Heterogeneity in meta-analysis. Handb Res Synthesis meta-analysis. 2019;3:453–70.

Article  Google Scholar 

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.

Article  CAS  PubMed  Google Scholar 

Poole C, Greenland S. Random-effects meta-analyses are not always conservative. Am J Epidemiol. 1999;150(5):469–75.

Article  CAS  PubMed  Google Scholar 

Williams R, Wood L, Collins C, Callister R. Effectiveness of weight loss interventions–is there a difference between men and women: a systematic review. Obes Rev. 2015;16(2):171–86.

Article  CAS  PubMed  Google Scholar 

Appel LJ, Clark JM, Yeh H-C, Wang N-Y, Coughlin JW, Daumit G, Miller ER III, Dalcin A, Jerome GJ, Geller S. Comparative effectiveness of weight-loss interventions in clinical practice. N Engl J Med. 2011;365(21):1959–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coutinho W, Halpern B. Pharmacotherapy for obesity: moving towards efficacy improvement. Diabetol Metab Syndr. 2024;16(1):6.

Article  PubMed  PubMed Central  Google Scholar 

Mäkinen V-P, Ala-Korpela M. Influence of age and sex on longitudinal metabolic profiles and body weight trajectories in the UK Biobank. Int J Epidemiol. 2024;53(3):dyae055.

Article  PubMed  PubMed Central  Google Scholar 

Hornburg D, Wu S, Moqri M, Zhou X, Contrepois K, Bararpour N, Traber GM, Su B, Metwally AA, Avina M. Dynamic lipidome alterations associated with human health, disease and ageing. Nat Metabolism. 2023;5(9):1578–94.

Article  CAS  Google Scholar 

Panyard DJ, Yu B, Snyder MP. The metabolomics of human aging: advances, challenges, and opportunities. Sci Adv. 2022;8(42):eadd6155.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Asharaf H, Thimothy G, George S, Jose J, Paily R, Josey J, Sajna S, Radhakrishnan R. Psychological impact of obesity: a comprehensive analysis of health-related quality of life and weight-related symptoms. Obes Med. 2024;45:100530.

Article  Google Scholar 

Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Reviews Cardiol. 2023;20(7):463–74.

Article  CAS  Google Scholar 

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salem V, Izzi-Engbeaya C, Coello C, Thomas D, Chambers E, Comninos A, Buckley A, Win Z, Al‐Nahhas A, Rabiner E. Glucagon increases energy expenditure independently of brown adipose tissue activation i